open access

Vol 2, No 1 (2011)
Review paper
Published online: 2011-03-24
Get Citation

Erythropoietin — the alternative treatment of anemia in infants

Sydonia Gołąbiowska-Staroszczyk, Michał Matysiak, Anna Adamowicz-Salach, Katarzyna Albrecht-Stanisławska, Agata Sobocińska-Mirska
Hematologia 2011;2(1):71-82.

open access

Vol 2, No 1 (2011)
REVIEW ARTICLES
Published online: 2011-03-24

Abstract

Anemia is one of the most common hematological problems in infants. The first 3 months of life are the period of special susceptibility to anemia development, because it may occur on the basis of a physiological decrease in morphological parameters of blood. The risk group of anemia are premature infants and term infants with additional complaints which have a negative influence on hematological parameters, for instance presence of serological incompatibility, infection or bleeding at birth or just after birth. Reduced production of erythropoietin has a key role in determining the occurrence of anemia the decrease in blood morphology in the first 3 months of life. Up to the recent years the only available treatment for this type of anemia was supplementary transfusion of packed red blood cells. Since the 1990s recombinant human erythropoietin (rHuEpo) has, in many cases, become an alternative treatment in such cases. The rich literature, created on the basis of researches carried out in many centres all over the world, confirms high effectiveness and safety of rHuEpo in the treatment of anemia in the first 3 months of life.
Hematologia 2011; 2, 1: 71–82

Abstract

Anemia is one of the most common hematological problems in infants. The first 3 months of life are the period of special susceptibility to anemia development, because it may occur on the basis of a physiological decrease in morphological parameters of blood. The risk group of anemia are premature infants and term infants with additional complaints which have a negative influence on hematological parameters, for instance presence of serological incompatibility, infection or bleeding at birth or just after birth. Reduced production of erythropoietin has a key role in determining the occurrence of anemia the decrease in blood morphology in the first 3 months of life. Up to the recent years the only available treatment for this type of anemia was supplementary transfusion of packed red blood cells. Since the 1990s recombinant human erythropoietin (rHuEpo) has, in many cases, become an alternative treatment in such cases. The rich literature, created on the basis of researches carried out in many centres all over the world, confirms high effectiveness and safety of rHuEpo in the treatment of anemia in the first 3 months of life.
Hematologia 2011; 2, 1: 71–82
Get Citation

Keywords

recombinant human erythropoietin; anemia in the first three months of life; anemia of prematurity; treatment

About this article
Title

Erythropoietin — the alternative treatment of anemia in infants

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 1 (2011)

Article type

Review paper

Pages

71-82

Published online

2011-03-24

Bibliographic record

Hematologia 2011;2(1):71-82.

Keywords

recombinant human erythropoietin
anemia in the first three months of life
anemia of prematurity
treatment

Authors

Sydonia Gołąbiowska-Staroszczyk
Michał Matysiak
Anna Adamowicz-Salach
Katarzyna Albrecht-Stanisławska
Agata Sobocińska-Mirska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.